Naturally Occurring Stilbenoid TSG Reverses Non-Alcoholic Fatty Liver Diseases via Gut-Liver Axis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The gut-liver axis is largely involved in the development of non-alcoholic fatty liver disease (NAFLD). We investigated whether 2, 3, 5, 4'-tetrahydroxy-stilbene-2-O-β-D-glucoside (TSG) could reverse NAFLD induced by a high-fat diet (HFD) and whether it did so via the gut-liver axis. Results showed that TSG could reduce the accumulation of FFA and it did so by reducing the expression of L-FABP and FATP4. TSG regulated gut microbiota balanced and increased the protein expression of ZO-1 and occludin, which could improve the function of the intestinal mucosal barrier and reduce serum LPS content by about 25%. TSG reduced TL4 levels by 56% and NF-κB expression by 23% relative to the NAFLD model group. This suggests that prevention of NAFLD by TSG in HFD-fed rats is mediated by modulation of the gut microbiota and TLR4/NF-κB pathway, which may alleviate chronic low-grade inflammation by reducing the exogenous antigen load on the host.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 1×
“Drug treatment remains an important part of addressing these issues, which include insulin sensitizers (metformin [13] and thiazolidinediones [14]), vitamin E [15], and statins [16].”
BackgroundToll‐like receptors and adaptor molecules in liver disease: Update†
Seki, E., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22306 · Cited by 722 · cited 2×
“Activation of the transcriptional factor NF-κB, a downstream target of TLR-MyD88 signaling, is crucial to the inflammatory response in immune cells and is key to the development of NAFLD [11, 38].”
BackgroundRivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693 · cited 1×
“TLR4 signaling plays pivotal roles in the pathogenesis of non-alcoholic steatohepatitis [37].”
BackgroundBjörkbacka, H., Kunjathoor, V. V., Moore, K. J., Koehn, S., Ordija, C. M., Lee, M. A., Means, T., Halmen, K., Luster, A. D., Golenbock, D. T., et al. (2004) · Nature Medicine · doi:10.1038/nm1008 · Cited by 634 · cited 1×
“Myeloid differentiation factor 88 (MyD88) is a downstream adaptor protein for all TLRs, except TLR3 [10].”
BackgroundZhang, X., Zhao, Y., Zhang, M., Pang, X., Xu, J., Kang, C., Li, M., Zhang, C., Zhang, Z., Zhang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042529 · Cited by 615 · cited 1×
“Studies have shown that plant metabolites, such as resveratrol [17] and its analogs [18] and berberine [19] can improve the general health of mammals, and they may be suitable for the treatment of age- and NAFLD-related disorders.”
Background
Cited by
Yu, J., Marsh, S., Hu, J., Feng, W., & Wu, C. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/2862173 · Cited by 199
Self-citationChen, Y., Lin, Y., Lin, J., Yang, N., & Chen, M. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700903 · Cited by 77
Zhou, H., Ma, C., Wang, C., Gong, L., Zhang, Y., & Li, Y. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173976 · Cited by 73
Song, L., Bi, Y.-N., Zhang, P.-Y., Yuan, X.-M., Liu, Y., Zhang, Y., Huang, J.-Y., & Zhou, K. (2017) · BioMed Research International · doi:10.1155/2017/8417814 · Cited by 21
Metadata
- Authors
- Lin, P., Lu, J., Wang, Y., Gu, W., Yu, J., & Zhao, R.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-10-16
- Volume
- 10
- Issue
- 10
- Pages
- e0140346
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2221237499
- Cited by
- 43
- References
- 5
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.